Survey of 300 Rheums, GI, Derms - concerns w/ new biosimilars - majority say economics arent favorable to switch to bios
Tweet Content
Survey of 300 Rheums, GI, Derms - concerns w/ new biosimilars
- majority say economics arent favorable to switch to biosimilar
- Yet majority "very to somewhat” comfortable w/ biosimilars
- US: Slow biosimilar uptake due to disappointing costs https://t.co/DOhrfELssY https://t.co/f2iy9igq5d
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off